Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data

Joaquim Prado P. Moraes-Filho; Gerson Domingues; Décio Chinzon; Juliana Leite Soares Guedes; Cláudia Yang Santos; Schlioma Zaterka

doi:10.5114/pg.2022.112777

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

4/2022
vol. 17

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data

Joaquim Prado P. Moraes-Filho

¹

,

Gerson Domingues

²

,

Décio Chinzon

¹

,

Juliana Leite Soares Guedes

³

,

Cláudia Yang Santos

³

,

Schlioma Zaterka

¹

Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, SP, Brazil
Gastroenterology Department, Medical School, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Takeda Pharmaceuticals, Brazil

Gastroenterology Rev 2022; 17 (4): 266–273

DOI: https://doi.org/10.5114/pg.2022.112777

Data publikacji online: 2022/01/23

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Introduction
Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.

Aim
To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).

Material and methods
From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs).

Conclusions
Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.

Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data

Joaquim Prado P. Moraes-Filho 1 , Gerson Domingues 2 , Décio Chinzon 1 , Juliana Leite Soares Guedes 3 , Cláudia Yang Santos 3 , Schlioma Zaterka 1

Joaquim Prado P. Moraes-Filho

¹

,

Gerson Domingues

²

,

Décio Chinzon

¹

,

Juliana Leite Soares Guedes

³

,

Cláudia Yang Santos

³

,

Schlioma Zaterka

¹